Tango Therapeutics Inc
$ 9.63
-2.73%
05 Dec - close price
- Market Cap 1,296,940,000 USD
- Current Price $ 9.63
- High / Low $ 9.99 / 9.55
- Stock P/E N/A
- Book Value 1.43
- EPS -0.91
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.52 %
- 52 Week High 11.20
- 52 Week Low 1.03
About
None
Analyst Target Price
$13.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-17 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 | 2023-05-09 | 2023-03-27 |
| Reported EPS | -0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 | -0.32 | -0.33 |
| Estimated EPS | -0.07 | -0.35 | -0.3459 | -0.3428 | -0.37 | -0.34 | -0.31 | -0.28 | -0.34 | -0.34 | -0.35 | -0.35 |
| Surprise | -0.07 | 0 | -0.0141 | 0.0028 | 0.1 | 0.1 | -0.04 | -0.04 | 0.11 | 0.11 | 0.03 | 0.02 |
| Surprise Percentage | -100% | 0% | -4.0763% | 0.8168% | 27.027% | 29.4118% | -12.9032% | -14.2857% | 32.3529% | 32.3529% | 8.5714% | 5.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3144 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2025-10-18 20:54:22
Tango Therapeutics (TNGX) saw its stock price surge by 18.63% on October 13, 2025, reaching an intraday high of USD 8.59, and has reported significant gains over the past week, month, and year-to-date. Despite impressive stock performance, the company faces financial challenges including a net profit decline of 2.57%, negative EBITDA, and a return on equity of -107.86%, indicative of a risky position within the competitive biotechnology sector.
2025-10-16 23:25:41
This article from Investing.com Philippines reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. The body of the article appears to have encountered a client-side application error, preventing further details from being displayed.
2025-10-16 19:35:10
The Investing.com Nigeria article reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. However, the article itself appears to be experiencing a client-side application error, preventing the full content from loading.
2025-10-16 16:44:34
The article reports that Tango Therapeutics stock reached a new 52-week high of $9.69 USD. The Investing.com Canada page, however, encountered an application error when attempting to load the full content.
2025-10-15 22:41:44
Tango Therapeutics, a small-cap biotechnology company, reached a new 52-week high of $9.11 on October 14, 2025, reflecting a significant 21.51% gain over the past year. Despite this strong stock performance, the company faces financial challenges including a negative return on equity and a high price-to-book ratio, operating in a highly competitive sector.
2024-11-06 00:00:00
Tango Therapeutics announced positive clinical data for TNG462, showcasing durable activity across multiple tumor types, including NSCLC and pancreatic cancer, and moving it into full development with combination studies planned for 2025. The company is also introducing TNG456, a next-generation brain-penetrant PRMT5 inhibitor for glioblastoma and other solid tumors, while halting enrollment for TNG908 to focus resources on the other two candidates. These strategic shifts aim to enhance treatment options for MTAP-deleted cancers, including a new clinical collaboration with Revolution Medicines.
